Pharma Mar, S.A. (VIE:PHM)

Market Cap	1.44B -12.7%
Revenue (ttm)	221.39M +26.6%
Net Income	74.99M +187.0%
EPS	4.30 +188.6%
Shares Out	n/a
PE Ratio	19.21
Forward PE	23.74
Dividend	0.80 (0.96%)
Ex-Dividend Date	Jun 25, 2025

Volume	n/a
Average Volume	55
Open	79.75
Previous Close	79.75
Day's Range	79.75 - 83.15
52-Week Range	70.60 - 95.65
Beta	n/a
RSI	57.65
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 500
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.